Shots:
- Caris has launched Caris MI Clarity, an AI-driven prognostic test for postmenopausal pts with HR+/HER2-, node-negative early-stage breast cancer, designed to assess both early (0–5yrs.) & late (5–15yrs.) distant recurrence risk from a single test at diagnosis
- The test leverages Caris’ multimodal dataset, computational pathology & AI-driven ML to analyze digitized H&E slides and clinical data without requiring genomic sequencing, delivering results within 3 business days using routine pathology specimens
- Caris MI Clarity was validated through collaborations with ECOG-ACRIN Cancer Research Group & NRG Oncology using data from major breast cancer trials incl. TAILORx & NSABP B-42, supporting personalized treatment planning by differentiating evolving recurrence risks over time
Ref: PRnewswire | Image: Caris Lifesciences |Press Release
Related News: Multi4 Medical Receives CE Mark Approval for Multi4 System to Perform Outpatient Bladder Cancer Treatment
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
